Literature DB >> 24937786

Driving ability in schizophrenic patients: effects of neuroleptics.

Michael Soyka1, Sabine Kagerer, Alexander Brunnauer, Gerd Laux, Hans-Jürgen Möller.   

Abstract

Recent studies indicate that individuals with schizophrenia have a two-fold incidence of traffic accidents. Cognitive and psychomotor impairment as a core feature of schizophrenia and the effects of neuroleptic treatment play an essential role in this respect. Few experimental studies have been conducted so far looking at the effects of neuroleptics on driving ability in schizophrenia. Controlled, randomised trials are totally missing. The limited database indicates that most schizophrenic patients show significant impairment in cognitive functions relevant for driving ability compared to healthy controls. There is some but limited evidence that patients under novel atypical neuroleptics show less impairment compared to conventional neuroleptics. More clinical and experimental studies are warranted.

Entities:  

Keywords:  Driving ability; neuroleptics; neuropsychology; psychomotor performance; schizophrenia

Year:  2005        PMID: 24937786     DOI: 10.1080/13651500510029237

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  3 in total

1.  [Driving ability with affective disorders and under psychotropic drugs].

Authors:  G Laux; A Brunnauer
Journal:  Nervenarzt       Date:  2014-07       Impact factor: 1.214

2.  Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics.

Authors:  Alexander Brunnauer; Gerd Laux; Sarah Zwick
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-11       Impact factor: 5.270

3.  Neuropsychological assessment of driving ability and self-evaluation: a comparison between driving offenders and a control group.

Authors:  Christina Zingg; Dietrich Puelschen; Michael Soyka
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-05-16       Impact factor: 5.270

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.